The startup is scheduled to discuss its first scientific data in an oral presentation at the European Society for Medical Oncology Congress in October. Precede will simultaneously publish the data in a medical journal and platform for research use enabling them to see if the technology can reveal the vulnerability of tumors to certain mechanisms of action